May 26, 2022

FDA Updates Contrast Shortage Posting to Include Estimated Shortage Duration

The U.S. Food and Drug Administration (FDA) has updated its drug shortage postings for Iohexol (Omnipaque) Injection and Iodixanol (Visipaque) Injection to reflect product availability updates, including estimated shortage duration forecasts.

Most presentations forecast supply increasing through May and June, with a return to stocking levels by July. The FDA’s postings also include a link to a recent communication from GE Healthcare’s CEO.

Bayer’s Ultravist has also been added to the FDA’s Drug shortage page resulting from increased demand likely related to the GE shortage issues.

The American College of Radiology® (ACR®) has developed a resource page on the contrast media shortage. For more information, please contact Gloria Romanelli, JD, ACR Senior Director, Legislative and Regulatory Relations.